Visual performance in giant cell arteritis (temporal arteritis) after 1 year of therapy

Mark J Kupersmith, Regina Langer, Hal Mitnick, Robert Spiera, Harry Spiera, Marjorie Richmond, Stephen Paget

Abstract

Aims—To determine if patients with giant cell arteritis (GCA) treated with corticosteroids develop delayed visual loss or drug related ocular complications.

Methods—In a multicentre prospective study patients with GCA (using precise diagnostic criteria) had ophthalmic evaluations at predetermined intervals up to 1 year. The dose of corticosteroid was determined by treating physicians, often outside the study, with the daily dose reduced to the equivalent of 30–40 mg of prednisone within 5 weeks. Subsequently, treatment guidelines suggested that the dose be reduced as tolerated or the patient was withdrawn from steroids in a period not less than 6 months.

Results—At presentation, of the 22 patients enrolled, seven patients had nine eyes with ischaemic injury. Four eyes had improved visual acuity by two lines or more within 1 month of starting corticosteroids. No patients developed late visual loss as the steroid dose was reduced. At 1 year the visual acuity, contrast sensitivity, colour vision, and threshold perimetry were not significantly different from the 4–5 week determinations. At 1 year, there were no significant cataractous or glaucomatous changes. At 2 months, there was no difference in systemic complications between patients who received conventional dose (60–80 mg per day) or very high doses (200–1000 mg per day) of corticosteroids at the start or early in the course.

Conclusions—Patients with GCA related visual loss can improve with treatment. Corticosteroids with starting doses of 60–1000 mg per day, with reduction to daily doses of 40–50 mg per day given for 4–6 weeks, and gradual dose reduction thereafter, as clinically permitted, did not result in delayed visual loss. There were no significant drug related ophthalmic complications.

(Br J Ophthalmol 1999;83:796–801)

Giant cell arteritis (GCA) is a systemic illness which affects men and women older than 55 years of age (more often older than 65) which can cause severe visual loss in affected individuals unless treated early. The inflammation of the ophthalmic arterial branches leads to ischaemic disease of the orbit with profound optic neuropathy, retinal and choroidal infarction, and less commonly, ocular movement

limitation.^{1–4} Corticosteroid treatment must be started as soon as the diagnosis is suspected since in 10% to 33% of untreated patients, the second eye will lose vision within 1 day to 3 weeks.⁵ Unfortunately, the required long term (6–24 months) treatment with corticosteroids often leads to severe systemic complications such as osteoporosis, gastric ulcer, diabetes, high blood pressure, immunosuppression, depression, weight gain,^{6,7} and ocular complications such as cataract and glaucoma.^{8–11} Preliminary studies have suggested that an anti-inflammatory drug, methotrexate may be beneficial for GCA because its use permits lower doses of corticosteroids to be administered with concomitant reduction in complications.¹² However, one prospective study using low dose (7.5 mg/week) methotrexate showed no benefit on GCA or polymyalgia rheumatica.¹³

We established a clinical trial at three university medical centre rheumatology and neuro-ophthalmology services to compare conventional corticosteroid therapy with a combination of methotrexate and corticosteroid treatment to address the question of disease control and rate of drug related complications. Difficulties with recruitment precluded sufficient numbers to answer the question whether methotrexate is beneficial but the prospective collection of data has provided some results with respect to the following questions:

- (1) Do daily pharmacological doses of corticosteroids given for 1 year cause significant cataract development or elevation of intraocular pressure in the elderly? Can the total cumulative corticosteroid dose be correlated with any ophthalmic complication?
- (2) Can corticosteroid therapy improve the vision in an eye with ischaemic injury from GCA?
- (3) Does a short term (<7 days) initial daily dose of 200–1000 mg of corticosteroids cause more systemic complications than an initial dose of 40–60 mg?
- (4) Do patients with GCA experience visual loss vision at 1 year while on small doses or no corticosteroid?
- (5) Do the eyes of patients with GCA have a poorer vision at 1 year compared with the visual performance after 4–6 weeks of treatment?

Methods

Twenty two patients aged over 55 years with GCA who met criteria modified from the American College of Rheumatology¹⁴ (Table 1)

INN at Beth Israel
Medical Center
M J Kupersmith
R Langer

Department of
Ophthalmology New
York University School
of Medicine
M J Kupersmith
H Mitnick

Mount Sinai Medical
Center
R Spiera
H Spiera

Hospital for Special
Surgery, New York
M Richmond
S Paget

Correspondence to:
Mark J Kupersmith, MD,
INN at Beth Israel North,
170 East End Avenue, New
York, NY 10128, USA.

Accepted for publication
22 February 1999

Table 1 Criteria for diagnosis of giant cell arteritis (GCA)

- (1) Patients must have symptoms suggestive of GCA and a temporal artery biopsy (performed within 1 week of steroid initiation), with signs of panarteritis including chronic inflammatory cells, disruption of the internal elastic lamina, with or without giant cells, except for (2) or (3).
- (2) Patients with acute anterior or posterior ischaemic optic neuropathy with symptoms suggestive of GCA (polymyalgia rheumatica, temporal fossa headache, scalp tenderness, loss of appetite, jaw claudication, tongue claudication, weight loss, night sweats), and ESR >60 mm in the first hour (without other cause for elevated ESR—that is, blood dyscrasia, lymphoma, tuberculosis, renal failure) even if negative temporal artery biopsy.
- (3) Patients with symptoms suggestive of GCA and pulseless disease with ESR 60 mm in the first hour

for diagnosis, did not have factors that excluded them, and gave consent were entered into a randomised, prospective, placebo controlled study within 5 weeks of establishing the diagnosis. Patients were excluded if they had additional visual or systemic illnesses that contraindicated the use of corticosteroids or methotrexate or could complicate or bias the study (in fact no patients meeting criteria and giving consent were excluded).

Patients with symptoms or signs of ophthalmic involvement were examined by MJK immediately before or after the onset of visual disturbance. Baseline and all subsequent evaluations (1, 3, 6, and 12 months) included full ophthalmological evaluation with best corrected visual acuity testing using Bailey-Lovie logMAR chart under standard conditions, contrast sensitivity testing using Pelli-Robson charts under standard conditions,¹⁵ colour vision testing with Ishihara plates, applanation tonometry, slit lamp biomicroscopy after mydriasis to visually measure lens opacities, determination of relative afferent pupillary defect, dilated fundus examination with stereoscopic measurement of the horizontal and vertical cup/disc ratio, and visual field testing with the Humphrey 24-2 strategy.

For each eye, the visual acuity was expressed as decimal (20/20 = 1.0, finger counting = 0.012, hand movement = 0.006, light perception = 0.001, no light perception = 0), the lowest contrast seen in log units of contrast, the colour vision as the decimal of the number of correct/total number of colour test plates, the visual field threshold as mean deviation (MD) and pattern standard deviation (PSD) <5%. The visual field data were also scored using the advanced glaucoma intervention study protocol (AGIS score).¹⁶

The degree of opacification in the lens was measured using a modification of LOCSII.^{17, 18} Following pupillary dilatation >5 mm, with tropicamide 1%, the lens was examined and the degree of opacification in the nucleus, cortex, and posterior subcapsular zones was graded. Opacities were defined as being present only if they were visible against the red reflex, otherwise the grade was 0. "Aggregate" opacification was derived by mentally summing the area of the opacities from non-contiguous locations in one zone and determining if the sum was as large as an entire quadrant (grade 2) or just less than the quadrant (grade 1b) or a small, minor cluster (grade 1a). A separate grade was recorded for the cortical and the posterior subcapsular zones. Nuclear opacification was determined

using the slit beam slightly wider than the pupil and simply graded as clear or unclear.

All patients received daily corticosteroid therapy (range 40–1000 mg) after initial diagnosis. The starting dose was left to the clinical judgment of the referring treating physician. Over 4–6 weeks the daily steroid dose was reduced to the equivalence of 30–40 mg of prednisone at which time each patient was randomised to receive either methotrexate or placebo in addition to the steroids. Since not all the rheumatologists clinically managing the patients were study investigators, the following regimen for the prednisone therapy was only suggested:

The dose of prednisone was to be gradually decreased by 10 mg/week until 40 mg per day is reached by the end of the first month, then by 5 mg/week until 20 mg per day is attained at the end of the second month. Subsequent tapering should be by 2.5 mg per week until the drug is completely suspended. The prednisone taper should be halted or the dose increased by 5–10 mg/day or more in order to control the symptoms or signs if a relapse occurs. A relapse is defined as recurrence of symptoms of GCA after definite improvement by prednisone, followed by symptom normalisation upon resumption or increase of the prednisone dose. An increase in the erythrocyte sedimentation rate (ESR) alone is not used as the indication for increasing the steroid dose.

After 4–6 weeks of corticosteroids, patients were randomised to either the addition of oral placebo or methotrexate of 10 mg per week. At 1 year, if a remission was achieved, the methotrexate dose was to be reduced by 2.5 mg/month until it is completely withdrawn.

All patients received 1500 mg/day of calcium carbonate and 400 IU of vitamin D to prevent osteoporosis, folic acid 1 mg orally each day, a H₂ blocking agent or carafate 1 g daily to prevent gastrointestinal ulceration. No patient received other anti-inflammatory drugs, sulfa drugs, or other immunosuppressive agents. When necessary the appropriate agent was added to control blood pressure, blood glucose, or prevent worsening osteoporosis.

DATA ANALYSIS

In the patients with visual loss, the visual acuity at presentation was compared with the visual acuity at entry into the study which was after 4–6 weeks of corticosteroid therapy.

The mean and standard deviations were determined for all the visual measures at baseline and at 1 year and Student's test was used to determine significance. For each, visual variable values at baseline were subtracted from the 1 year values. Linear regression analysis was used to demonstrate correlation between total cumulative steroid dose and change in lens, total cumulative steroid dose and change in contrast sensitivity, change in contrast sensitivity and change in MD and PSD, and change in contrast and change in lens. Eyes with synthetic intraocular lens were omitted from lens related analyses (six eyes of four patients). Two eyes of one patient with

Figure 2 Changes in visual acuity at 1 year. Positive numbers indicate improvement and negative numbers, worsening. Frequency is expressed as number of eyes.

Figure 3 Change in contrast at 1 year from baseline expressed in log units $\times 10^{-1}$. Positive numbers indicate improvement and negative numbers, worsening. Frequency is expressed as number of eyes.

The total cumulative dose of corticosteroid did not correlate with the change in either lens measurement (Table 3).

The seven eyes with contrast sensitivity of 0.5 log units or less were more closely inspected to look for a possible subgroup of cataract development. Of these seven eyes, four had lens changes, one with minor (1a) cortical zone and one with minor (1b) posterior subcapsular zone changes. Two eyes had cortical changes less than one quadrant (1b). In these seven eyes, the MD improved in four, worsened in two, and was unchanged in one eye. The PSD improved in two and was unchanged in five eyes. Thus, there were no consistent data suggestive of visually significant cataract development.

Patients treated with 1000 mg of corticosteroid daily did not have higher total cumulative doses at 1 year than those patients initially treated with 40–60 mg daily. The mean cumulative dose of corticosteroid (methylprednisolone for intravenous and prednisone for oral use) was 5906 mg (SD 1955 mg). The total dose of prednisone was similar for patients with (5825 mg (2570)) and without visual loss (5938 mg (1644)), $p = 0.9$). There

was no difference in the cumulative steroid dose between the 12 patients who received methotrexate (6184 mg (2048)) and the 10 patients who received placebo (5436 mg (1600)), $p = 0.39$).

Corticosteroid associated systemic complications, none permanent, during the first 2 months of therapy required intervention in seven patients. Three patients required oral hypoglycaemic agents to lower elevated blood glucose and six others had elevation in blood glucose requiring no medication. No patient developed new systemic hypertension. One patient developed pneumonia requiring hospitalisation. One patient became psychotic on oral prednisone 40–60 mg several weeks after an uncomplicated initial intravenous methylprednisolone 1000 mg daily. One patient had mild euphoric personality changes. Two patients had a focal herpes zoster rash treated with an oral antiviral agent. After the first 2 months, there were no additional cases of hyperglycaemia or significant infection. There were no pathological fractures during the first 2 months of therapy. At 1 year there were two vertebral fractures and no hip fractures. As expected, there were numerous minor symptoms such as weight gain, water retention, acne, gastrointestinal discomfort, thin skin, hair thinning, hirsutism, and mood change.

Discussion

As described in earlier studies, patients with GCA associated visual loss can recover with corticosteroid treatment. In our patients, the improvement in acuity was noted within weeks of starting therapy and never after 1 month. One patient with acute (less than 2 hours) loss of vision and no light perception in an eye with an amaurotic pupil improved after receiving methylprednisolone 1000 mg daily. Of the four eyes that improved two lines or more on the visual acuity chart, only one received methylprednisolone 1000 mg/day. The others were treated with oral prednisone 200 mg daily.

All measures of visual performance after 1 year of therapy in patients with giant cell arteritis were fairly stable when compared with the measurements taken at approximately 4–5 weeks after initiating corticosteroid therapy (entry point into treatment trial). The more sensitive measures of vision, contrast sensitivity and threshold perimetry, showed no significant pattern of change and, in fact, in many eyes the improvement or worsening on one test was not paralleled by an improved result on another visual performance measure. However, because of fixation losses and false negative and positive errors, the results of threshold perimetry were probably less reliable than the other visual studies.

Patients can be given corticosteroids 200–1000 mg per day for a week without severe long term ocular or short term unmanageable systemic complications. Prednisone 40–80 mg daily for the next 3–5 weeks followed by a judicious dose reduction over months also appeared to be tolerated relatively well. In contrast, the high rate of complications in other studies probably resulted from protracted use

Table 3 Comparison of change in visual performance measures from baseline to 1 year for 44 eyes*

Linear regression coefficient	r ²
Change contrast and mean deviation	0.01
Change contrast and pattern standard deviation	0.01
Change contrast and cortical zone	0.02
Change contrast and posterior subcapsular zone	0.08
Change in cortical zone and cumulative steroid dose	0.008
Change in posterior subcapsular zone and cumulative steroid dose	0.02

*All eyes except as noted in methods.

of high dose steroids.⁷ The fact that in our study gradual reduction to 40 mg daily after 4–5 weeks was not associated with the onset of new visual loss suggests it is probably unnecessary to maintain patients on larger doses of prednisone for months. We are in the process of determining whether initial treatment with a short course of corticosteroids 200–1000 mg per day causes more late systemic complications such as hypertension, diabetes, osteoporosis, and pathological bone fractures than initial daily doses of 40–80 mg.

Although it appears that megadose (1000 mg) intravenous or 200 mg orally can be taken by the elderly without more complications than conventional lower dose corticosteroid, the optimal dose to possibly improve vision or prevent visual loss in the second eye has not been established by this or any other study. Anecdotal cases of visual loss developing after 1 week of up to prednisone 200 mg daily which reversed with 1000 mg daily have been described.¹⁹ Since treating patients with high doses of corticosteroid for the first 1–2 weeks seems unlikely to increase the incidence of complications, until it is established that lower doses are as effective, higher dose (200–1000 mg per day) therapy seems warranted in patients with visual loss and maybe even in those who have not experienced neurological or ophthalmological symptoms. There appear to be few reasons not to use 200 mg or more per day in cases with acute visual loss or in cases that are worsening while on conventional moderately high dose oral steroids (60–80 mg). Afterwards, unless there is a definite clinical flare up of GCA, the dose of corticosteroid should be reduced to the equivalent of 40 mg of prednisone within 4–6 weeks. Lowering the daily steroid dose thereafter as clinically tolerated appears to be prudent in that it appeared to be the reason for the reduced number of permanent or long term complications in this study.

We had two patients who developed loss of vision while receiving prednisone 60 mg and 80–120 mg per day, with both showing deterioration in less than 1 week into treatment. Numerous reports have documented the acute loss of vision in the first or second eye during the first 2 weeks of oral prednisone 40–100 mg per day^{20–27} and even in a patient treated with intravenous prednisone 1000 mg daily.²⁸ However, visual loss is more likely to occur in patients given prednisone in daily doses of less than 30 mg, such as are typically used for polymyalgia rheumatica.^{6–29–30} Patients have also been reported to lose vision if the prednisone is reduced too quickly, usually to less than 30 mg within 4 weeks^{31–32} or to 10 mg within 2 months.³³

In contrast, delayed visual loss following treatment for months with 20–30 mg per day of prednisone after initial therapy using 60–80 mg per day is rare. We had no patients who developed ischaemic visual loss after 1 or more months of treatment. Although repeat temporal artery biopsy 6 months to up to 9 years^{26–34} after corticosteroid treatment, may show continued or recurrent inflammatory changes, the

risk of visual loss in these patients is unknown. Because the population affected by GCA is also at risk for non-arteritic vascular occlusive disease, reports of central retinal artery occlusion or anterior ischaemic optic neuropathy occurring many months to years after what would be considered adequate treatment may not actually represent recurrence of arteritis. There are numerous reports which contain cases of ischaemic visual loss which appear to be non-arteritic.^{21–27–29–35} Unfortunately, some articles have poor documentation of the visual system findings that developed after months of treatment so no definite conclusion can be drawn from many of these reports.^{36–37} We could find three cases with definite GCA caused delayed visual loss, two following 2 months^{24–38} and one after 5 months of therapy,²³ but none after 1 or more years of treatment with doses of steroids considered adequate for GCA by most North American rheumatologists.

Lastly, the results in this small study differ from the results of earlier larger studies of longer duration that found significant ocular complications of chronic corticosteroid use. Glaucoma has been reported to develop in approximately 8% of patients on long term systemic therapy,⁸ although there is no clear correlation with dose or duration of therapy.^{9–10} The new onset of elevation of intraocular pressure occurred in 4% of patients (one case) without the development of glaucomatous cupping. Cataract formation, usually bilateral, is associated with dose and duration of the systemic corticosteroid therapy.⁹ The opacification typically begins in the posterior subcapsular region and eventually spreads to the cortex. After 1 year of systemic corticosteroids in our patients older than 55 years of age, significant cataractous changes or visual loss from lens opacification, determined by a reduction in visual acuity or contrast sensitivity, or worsening of the mean deviation of threshold perimetry, were not found. This was not unexpected since the prevalence of cataractous change, particularly posterior subcapsular opacification, appears to increase with duration longer than 1 year, typically longer than 5 years, of systemic corticosteroid use.³⁹

Supported by the AARP Andrus Foundation and New York Arthritis Foundation.

- 1 Wagener HP, Hollenhorst RW. Ocular lesions of temporal arteritis. *Am J Ophthalmol* 1958;45:617–30.
- 2 Russell RWR. Giant-cell arteritis: a review of 35 cases. *Q J Med* 1959;28:471–8.
- 3 Henkind P, Charles NC, Pearson J. Histopathology of ischemic optic neuropathy. *Am J Ophthalmol* 1970;69:78–90.
- 4 Wilkinson IMS, Russell R, Ross W. Arteries of the head and neck in giant cell arteritis. a pathological study to show the pattern of arterial involvement. *Arch Neurol* 1972;27:378–9.
- 5 Graham E, Holland A, Avery A, et al. Prognosis in giant cell arteritis. *BMJ* 1981;282:269–71.
- 6 Delecoeuillerie D, Jolly P, Cohen de Lara A, et al. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (10 year survey of 29 patients). *Ann Rheum Dis* 1988; 46:733–9.
- 7 Paget SA, Healey JH, Williams-Russo P, et al. Osteoporosis in steroid-treated patients with polymyalgia rheumatica and temporal arteritis: what is the magnitude and rate over 1 year. *Arthritis Rheum* 1992;35:S9.
- 8 Adhikary HP, Sells RA, Basu PK. Ocular complications of systemic steroid after renal transplantation and their association with HLA. *Br J Ophthalmol* 1982;66:290–1.

- 9 Godel V, Feiler-Ofry V, Stein R. Systemic steroids and ocular fluid dynamics. I. Analysis of the sample as a whole. Influence of dosage and duration of therapy. *Acta Ophthalmol* 1972;**50**:655–63.
- 10 Godel V, Feiler-Ofry V, Stein R. Systemic steroids and ocular fluid dynamics. II. Systemic versus topical steroids. *Acta Ophthalmol* 1972;**50**:664–76.
- 11 Urban RC, Cotlier E. Corticosteroid-induced cataract. *Surv Ophthalmol* 1986;**31**:102–10.
- 12 Hernandez C, Fernandez B, Ramos P, et al. Giant cell arteritis therapy: methotrexate as a steroid-sparing agent. *Arthritis Rheum* 1991;**34**:S73.
- 13 Van der Veen MJ, Dinant HJ, van Booma-Frankfort C, et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? *Ann Rheum Dis* 1996;**55**:218–23.
- 14 Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. *Arthritis Rheum* 1990;**33**:1122–8.
- 15 Pelli DG, Robson JG, Wilkins AJ. The design of a new letter chart for measuring contrast sensitivity. *Clin Vis Sci* 1988;**2**:187–99.
- 16 The Advanced Glaucoma Intervention Study Investigators. Advanced glaucoma intervention study. 2. Visual field testing scoring and reliability. *Ophthalmology* 1994;**101**:1445–55.
- 17 Chylack LT, Leske M, Sperduto R, et al. Lens opacities classification system. *Arch Ophthalmol* 1988;**106**:330–4.
- 18 Leske MC, Chylack LT, Sperduto R, et al. Evaluation of a lens opacities classification system. *Arch Ophthalmol* 1988;**106**:327–9.
- 19 Kupersmith MJ. *Neurovascular neuro-ophthalmology*. Heidelberg: Springer-Verlag, 1993:211.
- 20 Huston KA, Hunder GG, Lie JT, et al. Temporal arteritis: a 25 year epidemiologic, clinical and pathologic study. *Ann Intern Med* 1978;**188**:162–7.
- 21 Hollenhorst RW, Brown JR, Wagener HP, et al. Neurologic aspects of temporal arteritis. *Neurology* 1960;**10**:490–8.
- 22 Liu GT, Glaser JA, Schatz NA, et al. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. *Ophthalmology* 1994;**101**:1779–85.
- 23 Calamia KT, Hunder GG. Clinical manifestations of giant cell (temporal) arteritis. *Clin Rheum Dis* 1980;**6**:389–403.
- 24 Rosenfeld SI, Kosmorsky GS, Klingele TG, et al. Treatment of temporal arteritis with ocular involvement. *Am J Med* 1986;**80**:143–5.
- 25 Thystrup J, Knudsen GM, Mogensen AM, et al. Atypical visual loss in giant cell arteritis. *Acta Ophthalmol* 1994;**72**:759–64.
- 26 Cohen DN. Temporal arteritis: improvement in visual prognosis and management with repeat biopsies. *Trans Am Acad* 1973;**77**:74–85.
- 27 Aiello PD, Trautmann JC, McPhee TJ, et al. Visual prognosis in giant cell arteritis. *Ophthalmology* 1993;**100**:550–5.
- 28 Slavin M, Margolis AJ. Progressive anterior ischemic optic neuropathy due to giant cell arteritis despite high-dose intravenous corticosteroids. *Arch Ophthalmol* 1988;**106**:167.
- 29 Beevers DG, Harpur JE, Turk KAD. Giant cell arteritis: the need for prolonged treatment. *J Chron J Dis* 1973;**26**:571–84.
- 30 Sorensen PS, Lorenzen I. [Giant-cell arteritis, temporal arteritis, and polymyalgia rheumatica.] [Danish] *Ugeskrift for Laeger* 1975;**137**:1135–41.
- 31 Myles AB, Perera T, Ridley MG. Prevention of blindness in giant cell arteritis by corticosteroid treatment. *Br J Rheumatol* 1992;**31**:103–5.
- 32 Meli B, Landau K, Gloor BP. Die tucken der riesenzellarteriitis aus ophthalmologischer sicht. *Schweiz Med Wochenschr* 1996;**126**:1821–8.
- 33 Healey LA, Wilske KR. Manifestations of giant cell arteritis. *Med Clin NA* 1977;**61**:261–70.
- 34 Blumberg S, Giansiracusa DF, Docken WP, et al. Recurrence of temporal arteritis. clinical recurrence nine years after initial illness. *JAMA* 1980;**244**:1713–14.
- 35 Cullen JF. Temporal arteritis occurrences of ocular complications seven years after diagnosis. *Br J Ophthalmol* 1972;**56**:584–8.
- 36 Hamilton CR Jr, Shelley WM, Tumulty PA. Giant cell arteritis: including temporal arteritis and polymyalgia rheumatica. *Medicine* 1971;**50**:1–27.
- 37 Kyle V, Hazelnan BL. Treatment of polymyalgia rheumatica and giant cell arteritis. 1. steroid regimens in the first two months. *Ann Rheum Dis* 1989;**48**:658–61.
- 38 Faarvang KL, Pontoppidan Thyssen E. Giant cell arteritis: loss of vision during corticosteroid therapy. *J Intern Med* 1989;**225**:215–16.
- 39 Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. *N Engl J Med* 1997;**337**:8–14.